Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BBio bOPV vs Licensed bOPV in Children and Infants
NCT02766816Phase 3Completed
- Sponsor
- Bilthoven Biologicals
- Start
- Jun 2016
- Primary completion
- Feb 2018
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of bivalent oral poliovirus vaccine in poliomyelitis, sponsored by Bilthoven Biologicals. Started Jun 2016; status: completed.
02
Drugs
bivalent oral poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT02766816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02766816.